Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

NurExone Biologic Inc. (V:NRX)

Business Focus: Biotechnology & Medical Research (NEC)

INK Edge Outlook

Insider Chart - Past 6 Months

Insider Filings

Latest 10 SEDI filings for NRX within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Mar 27, 2024 17:05 ET
Gross Proceeds Close of $4M CAD Generated for NurExone From Warrants Exercise
NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”), is pleased to announce that, the Company completed a combined exercise and expiration of 12,682,340 common share purchase warrants issued pursuant to a private...
Read full article
Mar 22, 2024 17:04 ET
In Preparation for Expected Human Clinical Trials, NurExone Signs Agreement for Large Scale Preclinical Testing for Its Spinal Cord Injury Therapy, ExoPTEN
NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company, developing regenerative medicine therapies, is proud to announce a strategic service agreement with Vivox Ltd. (“Vivox”), a...
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
N/A
--
--
Price to Sales - TTM
--
2.78
3.45
Price to Book - most recent quarter
37.98
2.66
2.04
Price to Cash Flow per share - TTM
--
6.39
10.35
Price to Free Cash Flow per share - TTM
--
24.85
12.34
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Mar 15, 2024493-74,349
Feb 29, 202474,84234,268
Feb 15, 202440,57440,151
See Short Report

Business Summary

Sector:  Healthcare Industry:  Biotechnology & Medical Research

NurExone Biologic Inc. is a biopharmaceutical company. The Company is developing and commercializing an exosome therapy ExoTherapy production platform and products for a global market. It is involved in the development of ExoPTEN, the first ExoTherapy-based product for acute Spinal Cord Injuries (SCI). The Company is developing treatment for the reversal or reduction of paralysis following spinal cord injury (SCI) using Exosomes (membrane-bound extracellular vesicles). This technology, subject to conducting clinical trials and receiving Food and Drug Administration (the FDA) approval, can be used in various conditions such as SCI, Brain Trauma Injury (BTI), and potentially other brain and neurological indications.

See business summary

 

Twitter

Search (past week) for $NRX.CA NRX.V

  • No tweets found